Antibody specialist Genmab makes most of its money from drugs developed and commercialized by partners. Acquiring ProfoundBio brings antibody drug conjugates that Genmab can develop on its own as it continues diversifying its business beyond strategic alliances.
The post Genmab Adds More ADC Firepower With $1.8B ProfoundBio Acquisition appeared first on MedCity News.